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y 5, 2013.he aim of the present study was to evaluate whether elevated cardiac troponin T (cTnT) was independently
associated with an increased all-cause mortality or risk of cardiovascular events and amputation among patients
with peripheral arterial disease (PAD).Background PAD patients often have impaired renal function, and the blood concentration of cardiac troponin often increases
with declining glomerular ﬁltration rate.Methods The cohort consisted of 1,041 consecutive PAD patients (653 males, 388 females, age 70.7  10.8 years,
Rutherford stages 2 to 5) undergoing endovascular peripheral revascularization.Results At baseline, measurable cTnT levels (0.01 ng/ml) were detected in 21.3% of individuals. Compared with patients
who had undetectable cTnT levels, those with cTnT levels 0.01 ng/ml had higher rates for mortality (31.7% vs.
3.9%, respectively; p < 0.001), myocardial infarction (4.1% vs. 1.1%, respectively; p ¼ 0.003), and amputation
(10.1% vs. 2.4%, respectively; p < 0.001) during a 1-year follow-up. In adjusted Cox regression models, cTnT
levels 0.01 ng/ml were associated with increased total mortality (hazard ratio [HR]: 8.14; 95% conﬁdence interval
[CI]: 3.77 to 17.6; p < 0.001) and amputation rates (HR: 3.71; 95% CI: 1.33 to 10.3; p ¼ 0.012).Conclusions cTnT is frequently elevated in PAD patients and is associated with higher event rates in terms of total mortality
and amputation. Even small cTnT elevations predict a markedly increased risk that is independent of an impaired
renal function. (Troponin T as Risk Stratiﬁcation Tool in Patients With Peripheral Arterial Occlusive Disease;
NCT01087385) (J Am Coll Cardiol 2014;63:1529–38) ª 2014 by the American College of Cardiology FoundationSee page 1539Cardiac troponin T (cTnT) is a component of the contractile
apparatus of cardiomyocytes and an established sensitive
biomarker of myocardial cell injury. Therefore, testing for this
biomarker is recommended for the diagnosis of myocardial
infarction in the clinical setting of an acute coronary syndrome
(ACS) (1).An elevated cTnT level is associatedwith an adverse
outcome after ACS (2,3) in patients with chronic heart failure
(4,5), acute pulmonary embolism (6), and end-stage renal
disease (ESRD) (7,8) and in the general population (9–12).
The clinical signiﬁcance of detectable cTnT among patients, University Heart Center Bad Krozingen, Bad
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13; revised manuscript received April 18, 2013,with peripheral arterial occlusive disease (PAD) is unknown.
Recently, some investigations have reported that elevated
cTnT levels may also be of prognostic value in patients with
acute limb ischemia (13,14). However, cardiac troponin levels
often increase with a declining glomerular ﬁltration rate, and
many PAD patients have impaired renal function (15,16).There is evidence that chronic kidney disease itself is associated
with an increased cardiovascular mortality (17,18). Elevated
cTnT levels are also associated with other vascular risk factors,
such as age, male sex, and diabetes (9,19,20). This study was
performed to deﬁne the distribution and determinants of
measurable cTnT among symptomatic PAD patients and to
explore its prognostic impact on mortality, amputation rates,
and cardiovascular outcomes during follow-up.
Figure 1 Study Design
ACS ¼ acute coronary syndrome(s);
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1530Methods
Study design and participants.
This retrospective single-center
study enrolled 1,065 consecutive
symptomatic PAD patients at
Rutherford stages 2 to 5 (Fon-
taine stages IIb to IV). Patients
were admitted to our university
teaching hospital between January
2007 andDecember 2007 for urgent
or elective endovascular revasculari-
zation. The ankle-brachial index and
diagnostic workup by a color-coded
duplex scan were routinely used be-
fore angiography to conﬁrm the
diagnosis of PAD and to deter-mine the therapeutic strategy. All patients were followed
for a period of at least 12 months or until death. Most
of the patients were regularly seen in the outpatient depart-
ment for diagnostic follow-up and were asked to answer
a standardized questionnaire. To obtain information about
mortality and vascular morbidity, we reviewed medical
records and contacted the patients and their general practi-
tioners. Outcome data were available for 1,012 patients
(95.0%) (Fig. 1). The protocol was approved by the lo-
cal ethics committee and registered at ClinicalTrials.Gov
(NCT01087385).
The exclusion criteria were all conditions that may
acutely increase cTnT levels. Myocardial ischemia or clinical
symptoms indicating unstable angina pectoris or ACS with-
in the previous 14 days resulted in exclusion from analysis.
Additional exclusion criteria were acute pulmonary embolism,cTnT ¼ cardiac troponin T; PAD ¼ peripheral arterialaortic dissection, New York Heart Association functional
class III or IV heart failure, cardiomyopathy, endocarditis/
myocarditis, external electrical cardioversion for atrial ﬁbril-
lation, and heart surgery within the previous 14 days. By
contrast, chronic kidney disease (CKD) and impaired renal
function were not exclusion criteria.
Laboratory assessment. Blood samples were collected
upon hospital admission. cTnT was measured with the
fourth-generation assay Elecsys troponin T using a Cobas
6000 e601 system (Roche Diagnostics, Mannheim, Ger-
many) according to the recommendations of the manu-
facturer. The 99th percentile value for the reference
population used by the manufacturer of the assay was 0.01
ng/ml, and the lowest level at which the coefﬁcient
of variation was <10% was 0.03 ng/ml (21). A cutoff value
of 0.01 ng/ml, which corresponds to the 99th percentile of
a reference population and the lowest level of detection, was
chosen to deﬁne an elevated cTnT level (22). Measurement
of cTnT was routinely performed in all PAD patients upon
hospital admission. However, the cTnT values were missing
for 7 patients, who were censored from further statistical
analysis (Fig. 1).
In addition, laboratory testing included automated and
standardized testing of serum creatinine levels. The esti-
mated glomerular ﬁltration rate (eGFR) was determined by
the Cockcroft-Gault formula and classiﬁed using standards
set forth by the National Kidney Foundation Disease
Outcomes Quality Initiative (23). According to these stan-
dards, we deﬁned an impaired renal function as an eGFR
concentration of <60 ml/min.
Baseline characteristics, comorbidities, and medication.
Assessment of atherosclerotic disease and cardiovascular riskdisease.
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1531factors was based on clinical history, clinical examination, and
laboratory test results. Patients were interviewed about
a history of coronary heart disease, ischemic cerebral infarction
or transient ischemic attack, and PAD. Patients’ smoking
status, classiﬁed as currently smoking versus never or previ-
ously smoked combined, was obtained using a standardized
questionnaire. Diabetes mellitus was diagnosed in accordance
with the World Health Organization classiﬁcation (24).
Arterial hypertension was deﬁned by a systolic blood pressure
of more than 140 mm Hg, a diastolic blood pressure of more
than 90 mm Hg, or both on at least 2 occasions or by the use
of antihypertensive drugs (25). Hypercholesterolemia was
deﬁned as a fasting cholesterol level exceeding 200 mg/dl, a
low-density lipoprotein cholesterol level of at least 130 mg/dl,
or both on at least 2 occasions or by the use of lipid-lowering
drugs (26). Finally, patient medications were also recorded.
Clinical evaluation and ECG registration. Seventeen
patients in the initial cohort had had an ACS within the
previous 14 days before study entry and were censored from
further statistical analysis (Fig. 1). There was no clinical
evidence of myocardial ischemia among the remaining pa-
tients. We analyzed the patients’ electrocardiograms (ECG),
which were performed simultaneously with blood sampling
at the time of admission to the hospital. According to the
consensus document of the Joint European Society of Car-
diology (ESC), American College of Cardiology Foundation
(ACCF), American Heart Association (AHA), World
Heart Federation (WHF) Task Force for the Redeﬁnition of
Myocardial Infarction (1), we registered ECG changes that
might be indicative of acute myocardial ischemia, for
example: 1) ST-segment elevation at the J-point in 2
contiguous leads with the cut-off points of 0.2 mV in men
or 0.15 mV in women in leads V2 to V3 and/or 0.1 mV
in other leads; 2) horizontal or down-sloping ST-segment
depression of 0.05 mV and/or T-wave inversion of 0.1
mV in 2 contiguous leads; and 3) the presence of left bundle
branch block.
Patient outcomes. Differences between outcomes after 12
months were determined for patients with elevated and those
with normal cTnT concentrations. The primary outcomes
examined in this analysis included total mortality and ampu-
tation. Secondary outcomes included myocardial infarction,
ACS, and target limb revascularization. ACS was deﬁned as
a non–ST-segment and ST-segment myocardial infarction or
unstable angina resulting in admission to the hospital. All
reported events were conﬁrmed by a review of medical records.
Statistical analysis. If not stated otherwise, the statistical
analysis was performed using Statistical Package for Social
Sciences (SPSS Statistics version 20.0, IBM, Chicago,
Illinois). The baseline characteristics are reported as
percentages for categorical variables and mean  SD for
continuous variables. We used the chi-square test in cross-
tabulations and the Mann-Whitney U test to compare
metric variables. Differences in outcomes were compared
between patients with elevated and those with normal cTnT
concentrations. Cox proportional hazards models were usedto examine the relationship between the cTnT levels deter-
mined at baseline and the outcome events. In these models,
the cTnT level was examined as a categorical variable. The
Cox models sequentially added age, eGFR, and the presence
or absence of current smoking, diabetes, and critical limb
ischemia (CLI). Age and eGFR were modeled as continuous
variables. The ﬁnal model also excluded all patients with
ECG changes conformable with acute myocardial ischemia,
according to the latest consensus document of the Joint ESC/
ACCF/AHA/WHF Task Force for the Redeﬁnition of
Myocardial Infarction (1). All tests were 2-sided, and the
criterion for statistical signiﬁcance was a p value of <0.05.
Under conditions of competing risks, Cox regression
models can produce misleading results, so a competing risk
approach implemented in the software survival of R version
2.14.0 (R Development Team, R Foundation for Statistical
Computing, Vienna, Austria) was used. We plotted the
overall cumulative incidence of amputation outcomes and
mortality (death before and after amputation) stratiﬁed by
cTnT levels of <0.01 ng/ml and 0.01 ng/ml. Differences
in curves were tested using the log-rank test. Furthermore,
a reclassiﬁcation analysis was performed using the Hmisc
software package of R by Frank E. Harrell to quantify and
compare the concordance of different predictors for
mortality.Results
Baseline characteristics of the study cohort. The clinical
characteristics and demographic information available for
the deﬁnitive study cohort of 1,041 patients are summarized
in Table 1. The mean age of patients was 70.7 (10.8) years;
and 62.7% were males, 44.9% were known to have coronary
artery disease (CAD), and 12.0% had a history of cerebral
infarction.
Determinants of elevated troponin T. cTnT was detect-
able (0.01 ng/ml) in 222 patients (21.3%). Patients with
cTnT values 0.01 ng/ml were older, more likely to be male
or diabetic, and less likely to have hypercholesterolemia or to
be current smokers compared with patients with cTnT
values <0.01 ng/ml. An elevated cTnT concentration was
also associated with an impaired renal function (Fig. 2),
cardio- and cerebrovascular comorbidities, and severe PAD.
In patients with intermittent claudication (i.e., Rutherford
stages 2 and 3), a cTnT of 0.01 ng/ml was present in 54 of
623 cases (8.7%) compared with 168 of 418 patients (40.2%)
with CLI (i.e., Rutherford stages 4 and 5; p < 0.001). In
addition, PAD was localized more distally among patients
with a cTnT elevation. In 121 cases (54.5%), the revascu-
larization procedure involved the tibial or peroneal arteries
compared with 272 cases (33.2%) of patients with unde-
tectable cTnT (p < 0.001) (Table 1).
One-year outcomes. During a 1-year follow-up, 106
patients died (9.7%). In 14patients (1.4%), amajor amputation
was unavoidable, and 29 patients (2.9%) underwent minor
amputation. The overall amputation rate was 4.1% (Table 2).
Table 1 Characteristics of the Study Sample by Baseline Troponin T Concentration
Parameter
Total Cohort
(N ¼ 1,041)
cTnT <0.01 ng/ml
(n ¼ 819)
cTnT 0.01 ng/ml
(n ¼ 222) p Value
Demographics
Age, yrs 70.7  10.8 69.7  10.8 74.5  10.1 <0.001
Males 653 (62.7%) 498 (60.8%) 155 (69.8%) 0.015
Vascular risk factors and comorbidities
Current smoking 251 (24.1%) 234 (28.6%) 17 (7.7%) <0.001
Diabetes mellitus 424 (40.7%) 299 (36.5%) 125 (56.3%) <0.001
Arterial hypertension 889 (85.4%) 690 (84.2%) 199 (89.6%) 0.044
Hypercholesterolemia 828 (79.5%) 662 (80.8%) 166 (74.8%) 0.049
Coronary artery disease 467 (44.9%) 333 (40.7%) 134 (60.4%) <0.001
Prior cerebral infarction 125 (12.0%) 85 (10.4%) 40 (18.0%) 0.003
Prior peripheral vascular intervention 470 (45.1%) 378 (46.2%) 92 (41.4%) 0.224
Prior peripheral bypass surgery 87 (8.4%) 73 (8.9%) 14 (6.3%) 0.273
Prior amputation 82 (7.9%) 48 (5.9%) 34 (15.3%) <0.001
Chronic kidney disease (stages 3 to 5) 400 (38.4%) 237 (28.9%) 163 (73.4%) <0.001
End-stage renal failure 66 (6.3%) 5 (0.6%) 61 (27.5%) <0.001
PAD characteristics
Rutherford category 2 287 (27.6%) 259 (31.6%) 28 (12.6%) <0.001
Rutherford category 3 336 (32.3%) 310 (37.9%) 26 (11.7%) d
Rutherford category 4 128 (12.3%) 94 (11.5%) 34 (15.3%) d
Rutherford category 5 290 (27.9%) 156 (19.0%) 134 (60.4%) d
Revascularized arterial segments
Iliac artery 224 (21.5%) 192 (23.4%) 32 (14.4%) 0.003
Femoropopliteal artery 773 (74.3%) 612 (74.7%) 161 (72.5%) 0.545
Tibial or peroneal artery 393 (37.8%) 272 (33.2%) 121 (54.5%) <0.001
Endovascular revascularization procedures
Occlusion/recanalization 547 (52.5%) 427 (52.1%) 120 (54.1%) 0.650
POBA 170 (16.3%) 122 (14.9%) 48 (78.4%) 0.019
Bare-metal stent 882 (84.7%) 700 (85.5%) 182 (82.0%) 0.207
Drug-eluting stent 182 (17.5%) 144 (17.6%) 38 (17.1%) 0.921
Mechanical atherectomy 97 (9.3%) 83 (10.1%) 14 (6.3%) 0.091
Mechanical thrombectomy 65 (6.2%) 50 (6.1%) 15 (6.8%) 0.754
Local thrombolysis 64 (6.1%) 54 (6.6%) 10 (4.5%) 0.344
Bypass surgery 20 (1.9%) 16 (2.0%) 4 (1.8%) 0.978
Medication at discharge
Aspirin or other antiplatelet medication 997 (96.8%) 797 (97.4%) 200 (94.3%) 0.029
Vitamin K antagonists 212 (20.4%) 141 (17.2%) 71 (33.5%) <0.001
Beta-blocker 611 (59.4%) 462 (56.5%) 149 (70.6%) <0.001
ACE inhibitor or AT1 receptor antagonist 732 (70.3%) 581 (70.9%) 151 (68.0%) 0.408
Lipid-lowering drug 752 (72.2%) 631 (77.1%) 121 (57.1%) <0.001
Values are n (%). p Values refer to comparisons between patients with and those without elevated troponin T.
ACE ¼ angiotensin-converting enzyme; AT1 ¼ angiotensin type-1; cTnT ¼ cardiac troponin T; PAD ¼ peripheral arterial disease; POBA ¼ plain old balloon angioplasty.
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1532Due to the progression of PAD, subsequent peripheral revas-
cularization procedures were required, and target limb revas-
cularization was performed in 24.3% of patients. Myocardial
infarction occurred in 1.9% of patients during follow-up, and
4.6% of patients were hospitalized with an ACS.
Total mortality and amputation risk according to
troponin T. Detectable cTnT levels ranged from 0.010 to
0.482 ng/ml. The distributions of cTnT by total mortality,
cardiac events, and amputation are demonstrated in Figure 3.
The mortality and amputation rates in patients with elevated
cTnT (0.01 ng/ml) were increased compared with those
with normal cTnT (Table 2), resulting in an unadjusted
hazard ratio (HR) of 9.87 (95% conﬁdence interval [CI]: 6.49to 15.0) for total mortality and 4.92 (95%CI: 2.68 to 9.03) for
amputation.
The cumulative incidence curves for amputation outcomes
and mortality (death before and after amputation) stratiﬁed
by cTnT <0.01 ng/ml and 0.01 ng/ml are demonstrated in
Figure 4. Comparing 1-year outcomes between patients with
cTnT values 0.01 ng/ml and those with <0.01 ng/ml,
mortality risk was 32.9% vs. 4.0% (log-rank test, p < 0.001),
respectively, and the risk of amputation was 9.9% vs. 2.4%
(log-rank test, p < 0.001), respectively.
No differences were observed for the incidence of
peripheral revascularization procedures. Regarding mor-
tality, similar associations were observed in a subgroup
Figure 2 Prevalence of Elevated Cardiac Troponin T
The prevalence of elevated cardiac troponin T (cTnT 0.01 ng/ml) among patients with intermittent claudication or critical limb ischemia (CLI), according to chronic kidney
disease (CKD) classiﬁcation using the estimated glomerular ﬁltration rate I: >90 ml/min; II: 60 to 89 ml/min; III: 30 to 59 ml/min; IV: 15 to 29 ml/min; V: <15 ml/min; or
dialysis.
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1533analysis of patients with CLI (HR: 9.51; 95% CI: 3.94 to
23.0) and patients with intermittent claudication (HR: 5.01;
95% CI: 3.08 to 8.17). A corresponding subgroup analysis
for amputation was not meaningful because only 2 ampu-
tations were performed in the subgroup of patients with
intermittent claudication.
After adjusting for age, eGFR and the presence or
absence of current smoking, diabetes, and CLI (Model 2),
the mortality risk in the total cohort remained increased,
with cTnT 0.01 ng/ml (HR: 4.64; 95% CI: 2.82 to 7.64;
p < 0.001). However, in multivariate analysis, the ampu-
tation risk was no longer signiﬁcant (HR: 1.86; 95% CI:
0.92 to 3.74; p ¼ 0.083) (Table 3).
The introduction of cTnT improved the prognostic dis-
crimination for mortality outcomes. The addition of cTnT
to Model 2 (c-statistic: 0.802  0.039) offered moderate
improvement (c-statistic with cTnT: 0.835  0.036). Quan-
tifying and comparing Harrell’s concordance, cTnT led
to an improvement of risk reclassiﬁcation (U-statistic:
0.30  0.06).
No patient at baseline included in this analysis had clinical
symptoms of unstable angina. Patients with an ACS withinTable 2 1-Year Mortality Rates and Incidence of Primary and Second
Event
No. in Total
Cohort (%)
(N ¼ 1,041)
No. of cTnT
<0.01 ng/ml (%)
(n ¼ 819)
Death 106 (9.7) 33 (3.9)
Amputation 42 (4.1) 20 (2.4)
Death or amputation 139 (12.9) 51 (6.1)
Target limb revascularization 252 (24.3) 204 (24.9)
Myocardial infarction 20 (1.9) 11 (1.1)
ACS 48 (4.6) 36 (4.4)
Values are n (%).
ACS ¼ acute coronary syndrome(s); CI ¼ conﬁdence interval; cTnT ¼ cardiac troponin T; HR ¼ hazardthe previous 14 days before blood sampling had been
excluded from the analysis. However, the interpretation of
ECGs performed upon admission to hospital revealed
signiﬁcant differences in the frequencies of ECG criteria
conformable with acute myocardial ischemia among patients
with and without elevated cTnT (Table 4). Repeating the
analysis after exclusion of all patients with any ECG changes
suggestive of acute myocardial ischemia (Model 3), the HRs
(and corresponding 95% CIs) were 8.14 (95% CI: 3.77 to
17.6; p < 0.001) for total mortality and 3.71 (95% CI: 1.33
to 10.3; p ¼ 0.012) for amputation.
Troponin T and myocardial infarction. During the 1-year
follow-up, we registered a total of 20 myocardial infarctions
(1.9%). Unadjusted analysis revealed a risk of myocardial
infarction for patients with cTnT values 0.01 ng/ml (HR:
3.75; 95% CI: 1.55 to 9.05) (Table 2). After adjusting for
age and eGFR, the association remained signiﬁcant (HR:
3.40; 95% CI: 1.23 to 9.45; p ¼ 0.019) (Model 1). In the
ﬁnal model after exclusion of all patients with ECG changes
that might indicate acute myocardial ischemia (Model 3),
these associations were no longer signiﬁcant (HR: 3.44; 95%
CI: 0.86 to 13.7; p ¼ 0.080).ary Outcomes According to Cardiac Troponin T at Baseline
No. of cTnT
0.01 ng/ml (%)
(n ¼ 222)
Unadjusted HR
(95% CI) p Value
73 (31.7) 9.87 (6.49–15.0) <0.001
22 (10.1) 4.92 (2.68–9.03) <0.001
88 (38.5) 7.84 (5.52–11.1) <0.001
48 (22.0) 1.10 (0.80–1.50) 0.563
9 (4.1) 3.75 (1.55–9.05) 0.003
12 (5.5) 1.56 (0.81–3.00) 0.182
ratio.
Figure 3 Cardiac Troponin T and Outcomes
The distribution of cTnT values in PAD patients according to total mortality (A), myocardial infarction (MI) (B), and amputation (C). Abbreviations as in Figure 1.
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In this study, we examined the associations between
elevated cTnT with total mortality and vascular outcomes in
PAD patients who underwent an angiographic workup and
a primary endovascular therapeutic approach for disease
stages 2 to 5 of the Rutherford classiﬁcation. Importantly,
we assessed patients without clinical evidence of acute
myocardial ischemia, according to the latest version of
the ESC/ACCF/AHA/WHF redeﬁnition of myocardial
infarction consensus document (1). Detectable cTnT levels
(0.01 ng/ml) were observed in 21.3% of subjects in our
cohort of symptomatic PAD patients. Elevated versus
normal cTnT levels, as deﬁned by the lower limit of
detection using the conventional fourth-generation cTnT
assay, was associated with several established vascular riskfactors (i.e., age, male sex, diabetes, and CKD) and with an
increased risk of death and amputation during follow-up.
Adjusting for potential confounders such as age, eGFR
and the presence or absence of current smoking, diabetes,
and CLI did not impair this relationship. The cutoff level
of 0.01 ng/ml revealed an 8.1-fold (95% CI: 3.8 to 17.6)
increased mortality risk and a 3.7-fold (95% CI: 1.3 to 10.3)
amputation risk among PAD patients.
Conversely, the associations between cTnT concentra-
tions and myocardial infarction were not signiﬁcant in our
ﬁnal model after adjusting for all potential confounding
factors. A similar observation has been made by Omland
et al. (27), who analyzed a cohort of 3,679 patients with
stable CAD. In their study, cTnT levels measured with
a high-sensitivity assay were detectable in 97.7% of CAD
Figure 4
Cumulative Incidence of Mortality and Amputation Stratiﬁed by cTnT Values 0.01 ng/ml and cTnT Values <0.01 ng/ml
During 1-Year Follow-Up
An elevated cardiac troponin T (cTnT) concentration is associated with a signiﬁcantly higher mortality and amputation rate (log-rank p <0.001).
Table 3
Association Between Cardiac Troponin T and Primary
Outcomes Using Cox Proportional Hazards Regression
Analysis
Event Model
Adjusted HR
(95% CI) p Value
Death 1 6.36 (3.93–10.3) <0.001
2 4.64 (2.82–7.64) <0.001
3 8.14 (3.77–17.6) <0.001
Amputation 1 4.75 (2.34–9.65) <0.001
2 1.86 (0.92–3.74) 0.083
3 3.71 (1.33–10.3) 0.012
Death or amputation 1 5.90 (3.94–8.85) <0.001
2 3.60 (2.39–5.43) <0.001
3 6.22 (3.33–11.6) <0.001
HRs and corresponding 95% CIs are from Cox proportional hazard regression analysis. Model 1,
adjustment for age and eGFR; Model 2, adjustment for age, eGFR, current smoking, diabetes, and
CLI. Model 3 ¼ Model 2 excluding patients with ECG changes suggestive of acute myocardial
ischemia.
CLI ¼ critical limb ischemia; ECG ¼ electrocardiographic; eGFR ¼ estimated glomerular ﬁltration
rate; other abbreviations as in Table 2.
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1535patients. Although increasing cTnT values were indepen-
dently related to higher mortality and heart failure rates
during a 5-year follow-up, no independent association was
observed between cTnT and myocardial infarction (27).
This ﬁnding is in contrast to observations in patients with
ACS in whom cTnT concentrations are considered bio-
markers of myocardial injury due to plaque rupture, intra-
coronary thrombosis, and myocardial ischemia and have
been demonstrated to predict negative outcomes (2).
The plasma cTnT levels in healthy subjects are thought to
result from a continuous microscopic loss of cardiomyocytes
during normal life (28). There is evidence that detectable
cTnT in subjects without clinical signs of acute myocardial
ischemia indicates an increased risk for future cardiovascular
events and unfavorable outcomes. The prevalence of cTnT
values 0.01 ng/ml in 3,557 subjects of the population-
based Dallas Heart Study was as low as 0.7% (9). That
study investigated cTnT levels with a conventional fourth-
generation cTnT assay, which was also used in our study.
Detectable cTnT levels were typically associated with high-
risk conditions, such as diabetes and advanced CKD.
Moreover, elevated cTnT levels correlated with the presence
of structural heart disease (e.g., left ventricular hypertrophy
or dysfunction) and a subsequent risk of all-cause mortality
(9,10,29).
Elevated concentrations of cardiac troponin are often
observed in patients with advanced CKD, but without
clinical signs of myocardial ischemia. In a large study that
included 733 asymptomatic patients with ESRD, a high
percentage of the patients had elevated concentrations of
troponin (21). The authors of that study reported cTnT
elevations in 82% of cases with a 0.01 ng/ml cutoff. In our
study, elevated cTnT was prevalent in 21.3% of patients, and
we also observed higher frequencies of elevated cTnT with
declining renal function. Therefore, it is plausible that theassociation between cTnT levels and adverse outcomes is at
least partly due to the presence of CKD, which by itself is
indicative of an adverse outcome. However, our data reveal
that cTnT levels 0.01 ng/ml remained an independent
predictor of death and amputation even after adjusting for
eGFR and other potentially confounding factors.
Only recently were cardiac troponin concentrations
identiﬁed as a possible risk stratiﬁcation tool in patients with
acute or chronic CLI. Rittoo et al. (13) described a high
prevalence of elevated cTnT among 39 patients with acute
limb ischemia (44%). The cumulative survival rates after 7
days were 53% for cTnT-positive patients and 100% for
cTnT-negative patients. However, the number of patients
included in that study was small. A previous investigation of
our study group highlighted the fact that an elevated cTnT
was predictive of a worse in-hospital outcome in terms of
Table 4
Prevalence of ECG Criteria Indicative of Acute
Myocardial Ischemia in Patients With and Without
Elevated cTnT*
Criteria
cTnT <0.01 ng/ml
(n ¼ 684)
cTnT 0.01 ng/ml
(n ¼ 159) p Value
ST-segment elevation 5 (0.7%) 5 (3.1%) 0.025
ST-segment depression 60 (8.8%) 33 (20.9%) <0.001
T-wave inversion 84 (12.3%) 48 (30.4%) <0.001
Left bundle
branch block
19 (2.9%) 8 (5.7%) 0.123
Values are n (%). *Criteria were taken from the consensus document of the Joint ESC/ACCF/AHA/
WHF Task Force for the Redeﬁnition of Myocardial Infarction (1).
Abbreviations as in Tables 2 and 3.
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patients with acute limb ischemia (14). Sarveswaran et al.
(30) followed 152 patients with chronic CLI and without
evidence of unstable CAD and discovered that elevated
cardiac troponin I (cTnI) independently predicted mortality
during a 2-year period (HR: 4.2; 95% CI: 1.3 to 12.7). In
other investigations, Landesberg et al. (31) and Kertai et al.
(32) demonstrated that low levels of asymptomatic troponin
elevation during the perioperative period are associated with
a poorer long-term outcome in patients undergoing major
vascular surgery. To our knowledge, the present study is the
ﬁrst one that evaluated the prognostic value of cTnT in
a large cohort of symptomatic PAD patients and provided
strong evidence of an independent relationship between
cTnT values 0.01 ng/ml and an increased mortality and
amputation risk.
The mechanisms responsible for the release of cardiac
troponin are most likely multifactorial and, in our patients,
may include transient, clinically silent myocardial ischemia
and small-vessel occlusions, myocardial strain, apoptosis of
cardiomyocytes, impaired renal function, and inﬂammatory
processes (33,34). Given the strong relationship between
CAD and PAD as clinical manifestations of atherosclerosis,
it is very likely that elevations in cTnT can result from
transient and less-severe ischemia as a consequence of
a mismatch between the oxygen supply and demand, and the
exposure of myocardial cells to cytokines.
Furthermore, in the special situation of CLI, the increase
in cardiac troponin appeared to be directly associated with
skeletal muscle damage and rhabdomyolysis (35–37). It
has been suggested that the release of necrotic muscle
constituents into the circulation may have direct toxic
effects on myocardial cells. However, Jaffe et al. (38)
observed an increased cTnT quantiﬁed with a fourth-
generation cTnT assay in 16 cases with skeletal muscle
myopathy. The diagnosis of myopathy had been suggested
by clinical history, examination, and increases of the crea-
tine kinase and was conﬁrmed by typical electromyographic
changes and skeletal muscle biopsy. These results are in
line with a previously published study reporting increased
creatine kinase and cTnT, but not cTnI, levels among
patients with idiopathic inﬂammatory myopathies (39).
However, this issue of speciﬁcity is far from settled. Thereis some evidence that cTnI is also expressed in myopathic
skeletal muscle tissue. Messner et al. (40) studied mRNA
expression of cTnT and cTnI in the skeletal muscle and
found that the mRNA of both cardiac troponin isoforms
was expressed in the skeletal muscles of patients with
myopathies (e.g., Duchenne muscular dystrophy). It has
been suggested that re-expression of the fetal cTnT iso-
form in response to injury may contribute to the increase in
cTnT levels (38,41). Another study investigated marathon
runners and discovered cTnT to be undetectable before the
race and to be elevated in 43% of the runners after the race.
In this study, the elevations in cTnT were also related to
higher inﬂammation markers (i.e., leukocyte and neutrophil
counts, C-reactive protein, interleukin-6) (42).
Study limitations. The present study has some important
limitations, which include the selection of patients included
in this retrospective trial, the use of a conventional fourth-
generation cTnT assay, and the fact that we did not perform
serial cTnT testing and ECG recordings. Therefore, we
cannot distinguish accurately between elevations due to
acute silent myocardial ischemia and chronic disease, which
is a major limitation in the interpretation of our results.
However, the patients enrolled in this study were admitted
to the hospital because of symptomatic PAD for angiog-
raphy and endovascular revascularization, and they had no
symptoms suggestive of ACS. In addition, our ﬁndings were
not signiﬁcantly attenuated after exclusion of patients with
ECG changes that might be indicative of acute myocardial
ischemia.
Previous studies have illustrated the fact that PAD
patients have a substantially increased risk of cardiovascular
morbidity and mortality (16,43,44). Among patients with
symptomatic PAD and without clinical symptoms suggest-
ing myocardial ischemia, an elevated cTnT is detectable in
every ﬁfth patient. According to our study, small elevations
of cTnT (0.01 ng/ml) measured with a conventional cTnT
assay predicted a markedly increased risk for death and
amputation during the 1-year follow-up. A highly sensitive
cTnT assay has recently been developed, allowing for the
measurement of concentrations 10-fold lower than those
measurable with conventional assays (45). These novel
high-sensitivity cTnT assays clearly improve diagnostic
performance in terms of an early and reliable diagnosis of
acute myocardial infarction and have widely replaced the
fourth-generation cTnT assay used in our study.
However, the higher sensitivity of these novel assays is
counterbalanced by a lower speciﬁcity. Thus, some of
these assays allow the detection of cTnT even in up to
90% in the general population (45). Despite a number of
trials providing evidence for the prognostic impact of
higher hs-cTnT levels in patients with stable CAD, ACS,
chronic heart failure, and ESRD (2,27,46,47), as well as
in the general population (4,10,34), the optimal decision
limit for the diagnosis of acute myocardial infarction and
the optimal cutoff value for prognostic purposes remain to
be determined (48).
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Cardiac troponin T is frequently elevated in PAD patients
and is associated with higher rates of events such as total
mortality and amputation. Even small cTnT elevations
predict a markedly increased risk that is independent of
impaired renal function. However, further studies are needed
to assess the prevalence, determinants, and prognostic
implications of cTnT elevations measured by conventional
or high-sensitivity assays in PAD patients.
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